Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
Volume 10.55M
Average 10.19M
ALLO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Allogene Therapeutics, Inc.NASDAQ: ALLO
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $29.13M fell 42.0% year over year, behind the -32.1% change in trailing-twelve-month research & development. Sequentially, it rose 1.8% from the prior quarter. Over 3 fiscal years it compounded at -16.3% a year.
Context
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -42.0% toward the trailing-twelve-month pace of -32.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 150.15M USD
- Year-over-year change
- -21.9%
- 4-year CAGR
- -9.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 150.15M | -21.9% |
| FY2024 | 2024-12-31 | 192.3M | -20.8% |
| FY2023 | 2023-12-31 | 242.91M | -5.3% |
| FY2022 | 2022-12-31 | 256.39M | +16.4% |
| FY2021 | 2021-12-31 | 220.18M | — |
Research & Development vs competitors
How ALLO compares with its peers on the latest reported figures
- ALLO's LTM Mar 2026 research & development of $129.09M is the highest of the 9 companies compared; the peer median is $88.85M.
- Its year-over-year change of -32.1% is the 8th highest of 9, against a peer median of -24.3%.
- Over three fiscal years its annual growth of -16.3% compares with a peer median of -1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $129.09M | -32.1% | -16.3% | — | |
| LTM Mar 2026 | $112.11M | -27.3% | +3.1% | 121.1% | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $94.68M | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $94.52M | -28.3% | +10.0% | 843.7% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| LTM Mar 2026 | $10.18M | -92.4% | -48.4% | 44.0% | |
| Peer median (excluding ALLO) | $88.85M | -24.3% | -1.0% | 121.1% | |
Competitors are the stored peer set for ALLO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 114.09M | 156K | 95K | 22K | 0 |
| Cost of Revenue | 0 | 14.3M | 0 | 0 | 12.36M |
| Gross Profit | 114.09M | (14.14M) | 95K | 22K | (12.36M) |
| Gross Margin | 100.0% | -9063.5% | 100.0% | 100.0% | — |
| Research & Development | 220.18M | 256.39M | 242.91M | 192.3M | 150.15M |
| Selling, General & Admin | 74.11M | 79.31M | 71.67M | 65.21M | 56.78M |
| Operating Expenses | 294.28M | 321.4M | 327.83M | 273.22M | 194.57M |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| EBITDA | (171.6M) | (326.12M) | (313.07M) | (243.33M) | (177.45M) |
| EBITDA Margin | -150.4% | -209050.6% | -329543.2% | -1106031.8% | — |
| Operating Income | (180.19M) | (335.54M) | (327.74M) | (273.2M) | (206.93M) |
| Operating Margin | -157.9% | -215087.2% | -344986.3% | -1241813.6% | — |
| Interest Income | 1.71M | 4.57M | 18.31M | 20.15M | 19.29M |
| Interest Expense | 0 | 0 | 0 | 181K | 1.08M |
| Other Income / Expenses | (1.86M) | (4.88M) | 472K | 16.05M | 16.05M |
| Income Before Tax | (182.05M) | (340.41M) | (327.27M) | (257.15M) | (190.89M) |
| Pre-Tax Margin | -159.6% | -218214.1% | -344489.5% | -1168850.0% | — |
| Income Tax Expense | 0 | 0 | 0 | 443K | 0 |
| Net Income | (182.05M) | (340.41M) | (327.27M) | (257.59M) | (190.89M) |
| Net Margin | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
| EPS (Basic) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| EPS (Diluted) | (1.34) | (2.38) | (2.09) | (1.32) | (0.87) |
| Weighted Avg Shares | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
| Weighted Avg Shares (Diluted) | 135.82M | 143.15M | 156.93M | 194.81M | 220.62M |
Allogene Therapeutics, Inc.
NASDAQ:ALLO
Intrinsic Alpha fair value
Locked
Current Price
$0.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.